Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

美卡素 - NMPA Drug Approval Details

Approvals/NMPA/Telmisartan Tablets

Approved

化学药品

Telmisartan Tablets

Boehringer Ingelheim International GmbH🇨🇳 National Medical Products Administration

Approval Date: Jan 17, 2022
Approval ID: 8EflbPxRLZI
Company: Boehringer Ingelheim International GmbH
Type: 化学药品

Approval Details

Approval Id: 8EflbPxRLZI
Approval Number: 国药准字HJ20171271
Generic Name: 替米沙坦片
Generic Name En: Telmisartan Tablets
Trade Name: 美卡素
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 80mg
Reg Date: 2022-01-17
Expired Date: 2027-01-16
Company Name: Boehringer Ingelheim International GmbH
Company Detail Path: /organization/boehringer-ingelheim-international-gmbh

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Jan 17, 2022

Approval ID

8EflbPxRLZI

Type

化学药品

Back to NMPA Approvals